Study of Enasidenib and Venetoclax in IDH2-Mutated Blood Cancers
-
- STATUS
- Recruiting
-
- End date
- Jul 6, 2023
-
- participants needed
- 48
-
- sponsor
- University Health Network, Toronto
Summary
The purpose of this research study is to see how safe and tolerable, and to find the highest or best dose, of an investigational combination of drugs called enasidenib and venetoclax, in patients with relapsed (the cancer has come back) or refractory (the cancer does not respond or have stopped responding to treatment) acute myeloid leukemia (AML, a type of blood cancer). This study will also see how useful the combination of enasidenib and venetoclax is in the treatment of patients with relapsed or refractory AML.
Description
This study will have two parts: Phase 1b and Phase 2. The part that patients may participate in will depend on when they join the study.
In the phase 1b portion of the study, small groups participants will receive increasing doses of venetoclax in combination with a flat dose of enadisenib until the highest dose or best dose of venetoclax that is safe and tolerable in combination with enadisenib is found.
In the phase 2 portion of the study, an additional group of participants will receive the highest or best dose of venetoclax found in the Phase 1b portion of the study with a flat dose of enadisenib to see how useful the combination is in treating relapsed or refractory acute myeloid leukemia (AML).
Details
| Condition | acute myeloblastic leukemia, Relapsed Cancer, Recurrent Cancer, Acute myeloid leukemia, Acute Myeloid Leukemia, IDH2 Gene Mutation, anll, Refractory Cancer, Acute Myelogenous Leukemia (AML), Cancer Refractory, Recurrent Carcinoma, acute myelogenous leukemia |
|---|---|
| Treatment | venetoclax, Enasidenib |
| Clinical Study Identifier | NCT04092179 |
| Sponsor | University Health Network, Toronto |
| Last Modified on | 6 December 2021 |
How to participate?
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreSimilar trials to consider
Browse trials for
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer